8-K: Gain Therapeutics: Rexaceract Shows Promise in Parkinson's Study

Gain Therapeutics announced positive long-term data from a Phase 1b study of its Parkinson's disease drug candidate, rexaceract, showing stabilization of motor symptoms over 12 months.

Summary

• Gain Therapeutics presented long-term open-label extension (OLE) data from its Phase 1b clinical study of rexaceract.
• The data, presented at the International Congress of Parkinsons Disease and Movement Disorders, showed stabilization of Movement Disorder Society-Sponsored Revision of the Unified Parkinsons Disease Rating Scale (MDS-UPDRS) scores over 360 days (12 months) of dosing.
• This stabilization suggests potential disease-modifying effects in Parkinson's disease (PD).
• Of the 13 evaluable patients, 12 completed the full 12-month OLE, with one more to finish in November 2026.
• MDS-UPDRS motor scores (Parts II and III) remained stable in 12 evaluable participants over the 12-month period, indicating no clinically meaningful progression of motor symptoms.
• A clinically meaningful change in PD progression is typically considered an increase of approximately 6 points in MDS-UPDRS Parts II and III combined annually.
• The company plans to submit a new Phase 2 study protocol to the FDA in the coming weeks and initiate the trial in Q1 2027.
• Preliminary long-term data indicate rexaceract is safe and well-tolerated over 12 months, with a lower incidence of treatment-emergent adverse events in the OLE compared to the initial three-month study.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic development, with positive early clinical data for rexaceract in Parkinson's disease, but acknowledges the inherent risks and long road to potential approval.

Positives

• Stabilization of MDS-UPDRS motor scores (Parts II and III) over 12 months in 12 evaluable patients, indicating no clinically meaningful progression of motor symptoms.
• The drug candidate, rexaceract, demonstrated potential disease-modifying effects in Parkinson's disease.
• Preliminary long-term safety and tolerability data suggest rexaceract is safe and generally well-tolerated over 12 months of dosing.
• Lower incidence of treatment-emergent adverse events observed in the nine-month open-label extension compared to the initial three-month administration.
• Reduction in glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF) suggests increased GCase activity in the brain, a positive indicator for Parkinson's disease treatment.
• Participants with high baseline CSF GluSph levels showed a decrease towards healthy levels and a quicker observed response to rexaceract.

Negatives

• The study is a Phase 1b, which is an early-stage trial, and results may not be predictive of later-stage trial outcomes.
• While 12 patients completed 12 months, one additional participant was scheduled to complete dosing in November 2026, meaning not all initial cohort data is fully finalized.
• The number of participants is small (13 evaluable patients), limiting the statistical power of the findings.

Risks

• Actual results could differ materially from forward-looking statements due to various risks and uncertainties.
• The development of current or future product candidates, including rexaceract, faces inherent risks.
• There is uncertainty regarding the timing of patient enrollment and completion of clinical studies, including extension studies.
• Regulatory approval timelines from the FDA or other bodies are subject to change and uncertainty.
• The design of the Phase 2 clinical study and FDA acceptance of the protocol are not guaranteed.
• The company's ability to enroll patients in the planned Phase 2 study is a potential risk.
• Results from early clinical trials, including open-label data, may not be predictive of final results or future trials.
• The company's ability to replicate positive results from earlier studies in current or future trials is not assured.

Future Outlook

The company expects to submit a new Phase 2 study protocol to the FDA in the coming weeks and initiate the Phase 2 clinical trial of rexaceract in people with Parkinson's disease in the first quarter of 2027. The Phase 2 study will be informed by insights from the Phase 1b study results and recent discussions with potential partners.

Management Comments

• The poster outlines long-term open-label extension (OLE) data from the Phase 1b clinical study of rexaceract showing stabilization of Movement Disorder Society-Sponsored Revision of the Unified Parkinsons Disease Rating Scale (MDS-UPDRS) scores over 360 days (12 months) of dosing, supporting the disease-modifying potential in Parkinsons disease (PD).
• The data, which includes safety, tolerability, and clinical scores from the Phase 1b nine-month study extension support continued development of rexaceract for PD.
• In the 12 evaluable participants, MDS-UPDRS motor scores were stable over the 12-month study period with rexaceract, demonstrating no clinically meaningful progression of motor symptoms on the MDS-UPDRS Parts II and III.
• Preliminary long-term data suggest that rexaceract is safe and generally well tolerated over 12 months of dosing.
• No new safety signals were observed and overall, a lower incidence of treatment-emergent adverse events occurred in Part 2 of the study (nine-month open-label extension) compared with Part 1 (initial three-month administration).

Industry Context

StockSavvy.ai notes that the development of disease-modifying therapies for Parkinson's disease is a significant unmet need. The focus on GCase activity and alpha-synuclein aggregation aligns with current research trends in neurodegenerative diseases. The stabilization of motor symptoms, if sustained and proven in larger trials, could position rexaceract as a key therapeutic agent in a competitive landscape.

Stakeholder Impact

• Shareholders: Positive news regarding clinical trial progress may lead to increased investor confidence and potentially influence stock price.
• Patients with Parkinson's Disease: Potential for a new disease-modifying therapy that could slow disease progression and improve quality of life.
• Healthcare Providers: May see a new treatment option for Parkinson's disease, pending further clinical validation and regulatory approval.
• Researchers: The data contributes to the understanding of GCase dysfunction and its role in Parkinson's disease progression.

Next Steps

• Submit a new Phase 2 study protocol to the FDA in the coming weeks.
• Initiate the Phase 2 clinical trial of rexaceract in people with Parkinson's disease in the first quarter of 2027.

Key Dates

Recommendation

The early positive data for rexaceract is encouraging, suggesting potential disease-modifying capabilities in Parkinson's disease. However, this is a Phase 1b study, and significant hurdles remain in terms of larger clinical trials, regulatory approval, and market adoption. Therefore, a 'hold' recommendation is appropriate, pending further data from Phase 2 trials.

Keywords

Parkinson's Disease, Rexaceract, Clinical Trial, Phase 1b, Movement Disorders, GCase, GBA1 Mutation, Neurology